Rapid Dose Therapeutics Corp. (CSE:DOSE)
Canada · Delayed Price · Currency is CAD 0.1000
+0.0100 (11.11%)
Jun 9, 2026, 5:19 PM EST
Rapid Dose Therapeutics Income Statement
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 |
| 2.78 | 2.09 | 1.02 | 0.72 | 1.75 | 0.76 | |
Revenue Growth (YoY) | 72.84% | 104.34% | 42.06% | -59.00% | 131.98% | 644.05% |
Cost of Revenue | 1.38 | 0.91 | 0.46 | 0.36 | 0.41 | 0.13 |
Gross Profit | 1.4 | 1.18 | 0.56 | 0.36 | 1.34 | 0.63 |
Selling, General & Admin | 3.31 | 3.55 | 2.45 | 2.46 | 2.99 | 1.5 |
Research & Development | 0.07 | 0.15 | 0.43 | 0.09 | 0.36 | 0.09 |
Operating Expenses | 4.48 | 5.35 | 3.65 | 3.9 | 5.65 | 2.26 |
Operating Income | -3.08 | -4.17 | -3.09 | -3.54 | -4.3 | -1.63 |
Interest Expense | -1.29 | -1.23 | -0.66 | -0.26 | -0.13 | -0.14 |
Interest & Investment Income | - | - | - | - | 0 | - |
Currency Exchange Gain (Loss) | - | - | - | -0 | 0.02 | -0.03 |
Other Non Operating Income (Expenses) | - | - | - | - | 0.01 | - |
EBT Excluding Unusual Items | -4.37 | -5.4 | -3.75 | -3.81 | -4.4 | -1.81 |
Impairment of Goodwill | - | - | - | - | -4.08 | - |
Other Unusual Items | - | - | -0.56 | - | - | - |
Pretax Income | -4.37 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 |
Net Income | -4.37 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 |
Net Income to Common | -4.37 | -5.4 | -4.31 | -3.81 | -8.49 | -1.81 |
Shares Outstanding (Basic) | 130 | 125 | 105 | 103 | 100 | 78 |
Shares Outstanding (Diluted) | 130 | 125 | 105 | 103 | 100 | 78 |
Shares Change (YoY) | 7.98% | 18.68% | 1.50% | 3.19% | 28.83% | 2.23% |
EPS (Basic) | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 | -0.02 |
EPS (Diluted) | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 | -0.02 |
Free Cash Flow | -0.87 | -1.15 | -2.29 | -0.86 | -3.04 | -1.63 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.01 | -0.03 | -0.02 |
Gross Margin | 50.44% | 56.59% | 55.21% | 49.67% | 76.76% | 83.40% |
Operating Margin | -110.68% | -200.07% | -302.45% | -493.36% | -245.55% | -216.45% |
Profit Margin | -157.17% | -259.18% | -422.03% | -530.42% | -484.47% | -239.04% |
Free Cash Flow Margin | -31.33% | -55.27% | -224.91% | -120.27% | -173.52% | -216.20% |
EBITDA | -2.65 | -3.95 | -2.75 | -3.2 | -3.82 | -1.25 |
EBITDA Margin | -95.17% | -189.66% | -269.93% | - | -218.31% | -165.21% |
D&A For EBITDA | 0.43 | 0.22 | 0.33 | 0.34 | 0.48 | 0.39 |
EBIT | -3.08 | -4.17 | -3.09 | -3.54 | -4.3 | -1.63 |
EBIT Margin | -110.68% | -200.07% | - | - | -245.55% | -216.45% |